EC proposes ''fairer'' mixed fee system to cover EMA's pharmacovigilance costs
This article was originally published in Scrip
Following strong criticism over its 2012 proposals for EU pharmacovigilance fees, and suggestions earlier this year that it was considering a flat fee system instead, the European Commission has gone for a compromise: a mixture of a flat fee and a range of individual payments for procedures such as safety referrals and periodic safety update reports (PSURs).
You may also be interested in...
The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.
Two EU bodies want to move forward with European Commission proposals on contamination of the environment by pharmaceutical substances.
Richard Torbett, who negotiated the UK's new voluntary pricing scheme, is to be the new chief executive of the ABPI.